Silvan Tuerkcan
Stock Analyst at JMP Securities
(2.27)
# 2,631
Out of 4,905 analysts
174
Total ratings
41.67%
Success rate
-3.08%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Silvan Tuerkcan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| JSPR Jasper Therapeutics | Maintains: Market Outperform | $70 → $12 | $3.33 | +260.36% | 6 | Jul 8, 2025 | |
| CRSP CRISPR Therapeutics AG | Reiterates: Market Outperform | $86 | $65.13 | +32.04% | 16 | Jun 27, 2025 | |
| NUVB Nuvation Bio | Reiterates: Market Outperform | $6 | $2.30 | +160.87% | 3 | Jun 25, 2025 | |
| EXEL Exelixis | Maintains: Market Outperform | $47 → $50 | $44.47 | +12.44% | 22 | Jun 23, 2025 | |
| ELEV Elevation Oncology | Reiterates: Market Perform | n/a | $0.38 | - | 9 | Jun 10, 2025 | |
| SLDB Solid Biosciences | Reiterates: Market Outperform | $15 | $6.39 | +134.74% | 3 | Jun 6, 2025 | |
| TSHA Taysha Gene Therapies | Maintains: Market Outperform | $5 → $6 | $2.57 | +133.46% | 13 | May 29, 2025 | |
| PRME Prime Medicine | Maintains: Market Outperform | $10 → $6 | $4.13 | +45.28% | 3 | May 20, 2025 | |
| BNTC Benitec Biopharma | Reiterates: Market Outperform | $20 | $11.04 | +81.16% | 12 | May 15, 2025 | |
| FHTX Foghorn Therapeutics | Reiterates: Market Outperform | $9 | $6.14 | +46.58% | 3 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $6 | $2.21 | +171.49% | 12 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $18 | $3.79 | +374.93% | 4 | Apr 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $20 | $5.65 | +254.30% | 12 | Apr 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $17 | $1.35 | +1,159.26% | 5 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $0.41 | - | 8 | Mar 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Outperform | $4 | $0.89 | +349.44% | 1 | Jan 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $21 | $3.50 | +500.00% | 10 | Dec 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.48 | - | 12 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $6 | $1.82 | +229.67% | 6 | May 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $240 → $280 | $291.80 | -4.04% | 3 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $18 → $18 | $9.87 | +82.37% | 1 | Jan 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $12.06 | - | 10 | Jan 19, 2023 |
Jasper Therapeutics
Jul 8, 2025
Maintains: Market Outperform
Price Target: $70 → $12
Current: $3.33
Upside: +260.36%
CRISPR Therapeutics AG
Jun 27, 2025
Reiterates: Market Outperform
Price Target: $86
Current: $65.13
Upside: +32.04%
Nuvation Bio
Jun 25, 2025
Reiterates: Market Outperform
Price Target: $6
Current: $2.30
Upside: +160.87%
Exelixis
Jun 23, 2025
Maintains: Market Outperform
Price Target: $47 → $50
Current: $44.47
Upside: +12.44%
Elevation Oncology
Jun 10, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $0.38
Upside: -
Solid Biosciences
Jun 6, 2025
Reiterates: Market Outperform
Price Target: $15
Current: $6.39
Upside: +134.74%
Taysha Gene Therapies
May 29, 2025
Maintains: Market Outperform
Price Target: $5 → $6
Current: $2.57
Upside: +133.46%
Prime Medicine
May 20, 2025
Maintains: Market Outperform
Price Target: $10 → $6
Current: $4.13
Upside: +45.28%
Benitec Biopharma
May 15, 2025
Reiterates: Market Outperform
Price Target: $20
Current: $11.04
Upside: +81.16%
Foghorn Therapeutics
May 15, 2025
Reiterates: Market Outperform
Price Target: $9
Current: $6.14
Upside: +46.58%
May 9, 2025
Downgrades: Market Perform
Price Target: $6
Current: $2.21
Upside: +171.49%
Apr 29, 2025
Reiterates: Market Outperform
Price Target: $18
Current: $3.79
Upside: +374.93%
Apr 21, 2025
Reiterates: Market Outperform
Price Target: $20
Current: $5.65
Upside: +254.30%
Mar 26, 2025
Reiterates: Market Outperform
Price Target: $17
Current: $1.35
Upside: +1,159.26%
Mar 14, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $0.41
Upside: -
Jan 8, 2025
Initiates: Market Outperform
Price Target: $4
Current: $0.89
Upside: +349.44%
Dec 12, 2024
Reiterates: Market Outperform
Price Target: $21
Current: $3.50
Upside: +500.00%
Nov 7, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $1.48
Upside: -
May 31, 2024
Reiterates: Market Outperform
Price Target: $6
Current: $1.82
Upside: +229.67%
Mar 5, 2024
Maintains: Buy
Price Target: $240 → $280
Current: $291.80
Upside: -4.04%
Jan 26, 2023
Maintains: Market Outperform
Price Target: $18 → $18
Current: $9.87
Upside: +82.37%
Jan 19, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $12.06
Upside: -